Responses
Oral Presentations
Abstract Session: Management of spondyloarthritis and psoriatic arthritis
OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.